Tony Mok, MD, a professor in the department of clinical oncology at the Chinese University of Hong Kong, discusses the next steps for pembrolizumab (Keytruda) as a treatment option for patients with non-small cell lung cancer (NSCLC) after the phase III KEYNOTE-042 trial. The current standard indication has been well-defined by a number of available studies as either monotherapy or in combination, says Mok. One of the next steps includes…

Three patients and two caregivers discuss their experiences with cancer immunotherapy: pembrolizumab (Keytruda) for prostate cancer, CAR T cell therapy for pediatric acute lymphoblastic leukemia, and nivolumab (Opdivo) for glioblastoma. #CRIsummit Denise Malone, mom and caregiver of the youngest panelist, Cole, stressed the importance of a team approach throughout his treatment. Cole was one of the first pediatric patients to receive CD-19 targeted chimeric antigen receptor (CAR) T cell therapy…

– Prostate Cancer Treatments Keytruda This video #33 in this series on on man’s journey with stage 4 prostate cancer. Prostate cancer is the most common cancer affecting men in the United States. From 2008 to 2012, the median age of diagnosis of prostate cancer was 66, and the incidence rate was 138 cases per 100,000 men per year. In this video I talk about PSA testing and the immunotherapy…